NXP Shares Decline After Forecast Fails to Impress Investors
Why the Federal Reserve's Building Renovation Costs $2.5 Billion
Milan Corruption Probe Casts Shadow Over Property Boom
Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom
How San Jose's Mayor Is Working to Build an AI Capital
Revenue in the period will be $3.05 billion to $3.25 billion, the Dutch company said in a statement on Monday. Though the midpoint of that range topped the average Wall Street estimate, some analysts predicted a number above $3.3 billion, according to data compiled by Bloomberg.
The outlook suggests that NXP is still contending with a turbulent industry. The company is heavily reliant on the automotive sector, which accounts for more than half of its revenue and has been hit by US President Donald Trump's tariff campaign. The levies have upended global supply chains and triggered uncertainty over customer orders.
Bernstein analyst Stacy Rasgon described the report as 'mostly fine,' but said it didn't quite match the 'whisper' numbers that some were hoping for.
The stock fell about 5% in extended trading. It had closed at $228.27 in New York on Monday, leaving it up almost 10% for the year.
NXP revenue fell 6% to $2.93 billion in the second quarter, roughly in line with analysts' estimates, according to data compiled by Bloomberg. The midpoint of its third-quarter forecast suggests that sales will decline 3% from a year earlier.
Third-quarter guidance 'may have disappointed the market,' Bloomberg Intelligence analyst Ken Hui said in a note. But it's consistent with his expectation that the company will keep inventories below the long-term target as NXP copes with 'an uncertain market backdrop.'
Chief Executive Officer Kurt Sievers struck an upbeat tone about the current quarter, saying it would reflect 'improvement in NXP's core end markets.' Earnings will be $2.89 to $3.30 a share, excluding some items, the company said. Analysts had projected $3.06 a share.
Second-quarter earnings amounted to $2.72 a share on that basis, beating the $2.68 estimate.
The CEO had said during the April earnings call that the second quarter was expected to mark 'a bit of a turning point,' as customer orders stabilized. Like its peers, NXP also has been struggling with a stubborn glut of chips that help power electric cars and manufacturing operations. This oversupply has weighed down sales for much of the industry for more than 18 months as demand for electric vehicles outside of China has fallen.
Weaker demand in the auto and industrial segments could be a drag on sales for NXP and rivals Infineon Technologies AG and STMicroelectronics NV. Last week, Renault SA slashed its guidance for this year's operating margins because of intensifying competition and a decline in the auto market. Stellantis NV on Monday reported a surprise first-half net loss.
Bloomberg Intelligence's Hui said in a note last week that automotive chipmakers 'may see stronger pricing pressure and the end of tariff-beating restocking demand from European customers after Renault cut its outlook' due to strong competition and declines in the vehicle market.
Additionally, industrial revenue recovery 'may be unsustainable after factory-automation leader Yaskawa reported 1Q orders that were weaker than expectations, particularly in China, and cut full-year forecasts to include tariff risks,' Hui wrote earlier this month.
--With assistance from Ian King.
(Updates with analyst commentary starting in fourth paragraph.)
Elon Musk's Empire Is Creaking Under the Strain of Elon Musk
A Rebel Army Is Building a Rare-Earth Empire on China's Border
Thailand's Changing Cannabis Rules Leave Farmers in a Tough Spot
How Starbucks' CEO Plans to Tame the Rush-Hour Free-for-All
What the Tough Job Market for New College Grads Says About the Economy
©2025 Bloomberg L.P.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Increasing Fundings and Investments, Advanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Growth
The global cancer diagnostics market, valued at USD 23.84 billion in 2024, is forecasted to grow at an 11.5% CAGR, reaching USD 70.80 billion by 2034. Key drivers include rising cancer cases, early detection initiatives, and technological advances like AI and liquid biopsies. The robust market includes leaders like Roche, Thermo Fisher, and expanding regions such as North America. Cancer Diagnostics Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Cancer Diagnostics Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)" report has been added to global cancer diagnostics market was valued at USD 23.84 Billion in 2024, driven by the rising prevalence of cancer and increasing awareness and early detection initiatives across the globe. The market is anticipated to grow at a CAGR of 11.50% during the forecast period of 2025-2034, with the values likely to reach USD 70.80 Billion by 2034 . Cancer diagnostics involves identifying cancer early to improve treatment outcomes. It typically starts with a clinical evaluation, including physical exams and medical history reviews. Diagnostic tests like imaging (X-rays, CT scans, MRIs, PET scans) detect abnormalities, while blood tests identify cancer markers. Biopsies, where tissue samples are examined under a microscope, confirm malignancy and provide detailed information about the tumour. Advanced methods, such as molecular testing, identify genetic mutations to guide personalised treatments. Screening programmes, like mammograms and colonoscopies, help detect cancer in its early stages. Accurate diagnostics are essential for effective treatment planning and monitoring of disease Diagnostics Market Growth Drivers Rising Merger and Acquisition Activities to Accelerate Market GrowthIncreasing demand for specialised cancer diagnostics and expanding healthcare access in emerging regions are major drivers of growth in the market. For instance, in December 2024, Metropolis Healthcare Limited announced its acquisition of Core Diagnostics, based in Delhi NCR, for USD 29.62 million. This acquisition aims to strengthen Metropolis' cancer testing services and enhance its footprint across Northern and Eastern India. With Core Diagnostics' extensive oncology portfolio and its established network of 200 cities, this move will drive market expansion and enhance diagnostic capabilities. The deal is set to propel Metropolis into a leading position, stimulating market growth in the forecast period by offering advanced cancer diagnostics to a wider Fundings and Investments to Meet Rising Cancer Diagnostics Market DemandGrowing investments in innovative cancer therapies and advancements in radiotherapy are key drivers for the expanding market. For instance, in November 2024, ARC Innovation, part of Sheba Medical Center, secured USD 5.1 million in funding for Starget Pharma, a startup developing targeted radioligand therapies for precise cancer diagnosis and treatment. With funding from the Cancer Focus fund, supported by MD Anderson Cancer Center, Starget Pharma plans to conduct clinical trials on cancers such as sarcomas and melanoma. This breakthrough in cancer diagnostics and treatment will likely enhance the efficacy of therapies and offer new diagnostic tools, positioning this technology to significantly impact the global market in the forecast Diagnostics Market TrendsAdvanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Market GrowthThe market is experiencing the rapid adoption of liquid biopsy technologies, which enable the detection of genetic mutations and biomarkers through blood samples. These non-invasive diagnostic tools are revolutionizing cancer detection by offering early diagnosis and real-time monitoring of treatment response. Liquid biopsy's increased accuracy and reduced patient discomfort are contributing to its growing popularity, particularly in precision oncology. As healthcare systems focus on improving early cancer detection, this technology's market demand is expected to rise significantly. Furthermore, advancements in molecular biology and bioinformatics will further boost its integration into clinical practice, expanding its market of Advanced Technologies to Impact the Cancer Diagnostics Market Value PositivelyArtificial intelligence (AI) and machine learning (ML) are playing a pivotal role in transforming the global cancer diagnostics market. AI-powered diagnostic tools enhance the accuracy of medical imaging, enabling early-stage cancer identification through pattern recognition and predictive analytics. These technologies not only improve diagnostic precision but also streamline workflow efficiencies, reduce human errors, and enhance treatment outcomes. With substantial investments being poured into AI in healthcare, the demand for AI-driven diagnostic solutions is growing. As the technology continues to evolve, its integration into cancer diagnostics will significantly increase market growth, driving future market value and development in the healthcare Partnerships Poised to Drive Cancer Diagnostics Market GrowthThe growing demand for precise and personalised cancer diagnostics is driving strategic collaborations in the field. For instance, in August 2024, Hitachi High-Tech Corporation and Gencurix, Inc. formed a partnership to develop cancer molecular diagnostics. By combining Hitachi's expertise in in vitro diagnostics and digital technologies with Gencurix's proficiency in biomarker discovery, the two companies aim to create advanced testing services. After a successful feasibility study, both companies are now set to commercialise these services in Japan. This collaboration will likely enhance the availability of molecular testing for cancer diagnosis, accelerating the growth of the global cancer diagnostics market by offering cutting-edge, more accurate diagnostic of Next-Generation Sequencing Technology to Increase Cancer Diagnostics Market SizeNext-generation sequencing (NGS) is a breakthrough technology that is rapidly transforming the global cancer diagnostics market. NGS offers high-throughput genomic analysis, enabling comprehensive testing of cancerous tissues to identify genetic mutations and potential therapeutic targets. This technology facilitates early detection of cancer, personalized treatment planning, and monitoring of therapeutic efficacy, contributing to better patient outcomes. The increasing availability of cost-effective NGS platforms and advancements in bioinformatics are driving its integration into clinical oncology practices. As a result, the NGS segment within the cancer diagnostics market is expected to experience substantial growth, adding significant value to the overall market. Key Questions Answered in the Cancer Diagnostics Market What was the global cancer diagnostics market value in 2024? What is the cancer diagnostics market forecast outlook for 2025-2034? What is market segmentation based on technology? How is the market segmented based on application? How is the market segmented based on clinical positioning? What are the major factors aiding the global cancer diagnostics market demand? How has the market performed so far and how is it anticipated to perform in the coming years? What are the market's major drivers, opportunities, and restraints? What are the major cancer diagnostics market trends? Which technology will lead the market segment? Which application will lead the market segment? Which clinical positioning will lead the market segment? Who are the key players involved in the cancer diagnostics market? What is the patent landscape of the market? What are the current unmet needs and challenges in the market? How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics? Key Attributes: Report Attribute Details No. of Pages 400 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $23.84 Billion Forecasted Market Value (USD) by 2034 $70.8 Billion Compound Annual Growth Rate 11.5% Regions Covered Global Supplier Landscape Agilent Technologies, Inc. F. Hoffmann-La Roche AG Thermo Fisher Scientific, Inc. Becton, Dickinson and Company Danaher Corporation GE Healthcare Abbott Siemens Healthineers Bio-Rad Laboratories, Inc. Illumina, Inc. PerkinElmer Inc. QIAGEN Hologic, Inc. Myriad Genetics, Inc. Sysmex Corporation NeoGenomics Laboratories, Inc. Foundation Medicine Grail Guardant Tempus Delfi Diagnotics Exact Sciences Corporation Cancer Diagnostics Market SegmentationMarket Breakup by Technology Blood-based Diagnostics In Vitro Diagnostics Immunoassays Histopathology Others Molecular Diagnostics cfDNA Testing DNA Methylation Analysis Gene Sequencing Polymerase Chain Reaction (PCR) In Situ Hybridization Isothermal Nucleic Acid Amplification Technology (INAAT) Microarrays Spectrometry Others Non-blood-based Diagnostics Imaging CT MRI PET Others Biopsy Comparative Analysis Solid Liquid Others Others Market Breakup by Indication Breast Cancer Lung Cancer Colorectal Cancer Prostate Cancer Cervical Cancer Blood Cancers (Leukemia and Lymphoma) Skin Cancer (Melanoma) Others Market Breakup by Clinical Positioning Screening Early Detection Treatment Guidance Treatment Response Assessment Market Breakup by Region North America Europe Asia Pacific Latin America Middle East and Africa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cancer Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
China's yuan undervaluation fuels euro zone trade deficit, German study shows
By Reinhard Becker and Sarah Marsh BERLIN (Reuters) -European companies are facing increasing pressure due to China's alleged currency manipulation to keep its yuan weak, a study by the German Economic Institute showed, as EU leaders prepared for a summit in Beijing aimed at navigating trade disputes. The yuan-euro exchange rate has remained stable in recent years despite significant shifts in cost relations between Europe and China, suggesting likely currency manipulation by the central bank, said Juergen Matthes, author of the study by the Institute (IW), which was seen by Reuters. Extremely low prices mean more European companies are sourcing intermediate goods from China, contributing to deindustrialisation on the continent, he said, urging the EU to take action. "The artificially low costs in China, driven by yuan undervaluation, are simply too attractive," Matthes said. Those companies that did not source their intermediate goods from China would lose market share to rivals who "fully exploit China's price advantages." The Chinese central bank did not immediately respond to a request for comment. EU leaders arrive in Beijing on Thursday for a top-level summit with China as both sides seek to navigate trade disputes amid broader global trade uncertainties. In response to allegations of currency manipulation, China has in the past said it was committed to implementing a managed floating exchange rate regime, based on market supply and demand. UNDER PRESSURE The study comes as European companies are under pressure from a surge in Chinese exports diverted from the United States and an appreciation of the euro against the dollar due to U.S. President Donald Trump's trade policies, economists say. Producer prices in Germany and the euro zone have surged since 2020 due to supply chain disruptions and the energy crisis, whereas prices in China have hardly increased. Yet, the exchange rate has barely moved, leading to a real appreciation of the euro against the yuan of over 40% between early 2020 and spring 2025, and deepening the euro zone trade deficit with China, the study shows. Normally, higher import purchases from the euro zone would boost the yuan as it drives up demand for the currency, but that has not been the case, said Matthes. President Trump labeled China a currency manipulator during his first term. The Treasury Department then dropped the designation in January 2020 as Chinese officials arrived in Washington to sign a trade deal with the U.S. Last month, the U.S. simply issued a stern warning to China, saying it stood out among key trading partners "in its lack of transparency around its exchange rate policies and practices." China said it upheld "multilateralism and respects multilateral consensus," was committed to keeping the renminbi exchange rate stable, and would not "engage in competitive currency devaluation." Matthes, however, said the Chinese central bank's behavior was "highly non-transparent." When adjusting the yuan exchange rate, which is only allowed to fluctuate within a narrow band, the dollar relationship plays a central role, as does a currency basket, he said. "But how this is done, exactly, no one outside China knows,' he said, and the euro is "collateral damage."
Yahoo
27 minutes ago
- Yahoo
FTSE 100 LIVE: Stocks surge as Trump strikes trade deals with Japan, the Philippines and Indonesia
This embedded content is not available in your region. The FTSE 100 (^FTSE) and European stocks soared higher on Wednesday as traders cheered news that US president Donald Trump has agreed to a "massive" trade deal with Japan, one of the country's largest trading partners. Posting on his social media site Truth Social, Trump said: "We just completed a massive Deal with Japan, perhaps the largest Deal ever made. Japan will invest, at my direction, $550 Billion Dollars into the United States, which will receive 90% of the Profits. This Deal will create Hundreds of Thousands of Jobs — There has never been anything like it. "Perhaps most importantly, Japan will open their Country to Trade including Cars and Trucks, Rice and certain other Agricultural Products, and other things." Japan's prime minister Shigeru Ishiba welcomed the announcement on Wednesday, adding that he expects the agreement to contribute to the world economy. "Japan's tariff rate, which had been set to increase to 25% on reciprocal tariffs, was kept at 15%. This is the lowest figure to date among countries with trade surpluses with the US," he said. Stocks: Create your watchlist and portfolio "The agreement does not include any reduction of tariffs on the Japanese side, including on agricultural products." "This is precisely the result of my consistent advocacy and strong lobbying of the US since I proposed 'investment over tariffs' to president Trump at our White House summit in February this year." Separately, Trump also announced that the US would levy a 19% tax on imports from the Philippines. He wrote on social media that the new tariff was part of a wider pact, in which the Philippines would remove duties on US goods and the two countries would cooperate militarily. "It was a beautiful visit, and we concluded our Trade Deal," Trump wrote on Truth Social, offering no further details about the apparent agreement. Meanwhile, Indonesia is set to pay a 19% tariff rate. Trump posted: "It is agreed that Indonesia will be Open Market to American Industrial and Tech Products, and Agricultural Goods, by eliminating 99% of their Tariff Barriers. "The United States of America will now sell American Made products to Indonesia at a Tariff Rate of ZERO, while Indonesia will pay 19% on all of their products coming into the U.S.A." London's benchmark index (^FTSE) was 0.4% higher in early trade - a fresh intraday high. Germany's DAX (^GDAXI) rose 0.7% and the CAC (^FCHI) in Paris headed 1.4% into the green. The pan-European STOXX 600 (^STOXX) was up 0.9% amid raised hopes that the EU might also be able to reach a trade deal with the US. Wall Street is set for a positive start as S&P 500 futures (ES=F), Dow futures (YM=F) and Nasdaq futures (NQ=F) were all in the green. The pound was 0.2% up against the US dollar (GBPUSD=X) at 1.3548. Follow along for live updates throughout the day: Indonesia to pay 19% tariff rate And the tariff news doesn't stop there... It has been announced that Indonesia is set to pay a 19% tariff rate. Trump posted: US also strikes trade deal with the Philippines Separately, Trump also announced that the US would levy a 19% tax on imports from the Philippines. He wrote on social media that the new tariff was part of a wider pact, in which the Philippines would remove duties on US goods and the two countries would cooperate militarily. "It was a beautiful visit, and we concluded our Trade Deal," Trump wrote on Truth Social, offering no further details about the apparent agreement. Compared to Japan, the Philippines is a relatively small trade partner with the US. Last year it sent around $14.2bn worth of goods to America, including car parts, electric machinery, textiles and coconut oil. Japan welcomes US trade deal Japanese prime minister Shigeru Ishiba welcomed the US-Japan trade deal on Wednesday. He said: It comes as Japan was the fourth largest single-country export market for US agriculture and related products in 2022, valued at nearly $17bn (£12.5bn). This is according to a report from the International Trade Administration. The US was the country's largest supplier of food and agricultural products, followed by the EU, China, Australia, and Thailand. Japan was also the biggest export market for US beef and pork, valued at roughly $5bn combined, and the second largest market for US corn, valued at $3.3bn. Asia and US overnight Stocks in Asia were higher overnight, with the Nikkei (^N225) surging 3.7% to a one-year high in Japan as the country struck a trade deal with the United States that lowers tariffs on its cars. US president Donald Trump said on Tuesday that a trade deal with Tokyo will include Japan paying a lower-than-threatened 15% tariff on shipments to the US. It also comes after an agreement with the Philippines that will see the US collect a 19% tariff rate on imports from there. Trump added that said representatives from the European Union were coming for trade negotiations on Wednesday, even as the EU was reportedly refining countermeasures in case of a deadlock before the 1 August deadline. Shares of carmakers surged on the back of the news with Mazda Motor (7261.T) rallying 17% and Toyota (7203.T) jumping more than 14%. Meanwhile the Hang Seng (^HSI) rose 1.3% in Hong Kong and the Shanghai Composite ( was 0.3% up by the end of the session. In South Korea, the Kospi (^KS11) added 0.4% on the day, with carmakers in the country also rising as the Japan deal fuelled optimism over potential progress in tariff negotiations between South Korea and the US. Across the pond on Wall Street, stocks inched to another record following some mixed profit reports. The S&P 500 (^GSPC) rose 0.1% to the all-time high it had set the day before, closing at 6,309.62, and the tech-heavy Nasdaq (^IXIC) slipped 0.4% from its own record, to 20,892.68. The Dow Jones (^DJI) gained 0.4% to end at 44,502.44. Coming up Good morning, and welcome back to our markets live blog. As usual we will be taking a deep dive into what's moving markets and happening across the global economy. To the day ahead we have data releases including US existing home sales for June, and the Euro Area's preliminary consumer confidence reading for July. Otherwise, earnings releases include Alphabet (GOOG) and Tesla (TSLA). Here's a snapshot of what's on the agenda: 7am: Trading updates: Kier, Compass Group, Mitie, Greencore, Marstons, ME Group 7am: UK Public Sector Net Borrowing 9.30am: Supreme Court to rule on appeal against LIBOR and EURIBOR convictions of Tom Hayes and Carlo Palombo 12pm: US weekly mortgage approvals data 3pm: US new home salesIndonesia to pay 19% tariff rate And the tariff news doesn't stop there... It has been announced that Indonesia is set to pay a 19% tariff rate. Trump posted: And the tariff news doesn't stop there... It has been announced that Indonesia is set to pay a 19% tariff rate. Trump posted: US also strikes trade deal with the Philippines Separately, Trump also announced that the US would levy a 19% tax on imports from the Philippines. He wrote on social media that the new tariff was part of a wider pact, in which the Philippines would remove duties on US goods and the two countries would cooperate militarily. "It was a beautiful visit, and we concluded our Trade Deal," Trump wrote on Truth Social, offering no further details about the apparent agreement. Compared to Japan, the Philippines is a relatively small trade partner with the US. Last year it sent around $14.2bn worth of goods to America, including car parts, electric machinery, textiles and coconut oil. Separately, Trump also announced that the US would levy a 19% tax on imports from the Philippines. He wrote on social media that the new tariff was part of a wider pact, in which the Philippines would remove duties on US goods and the two countries would cooperate militarily. "It was a beautiful visit, and we concluded our Trade Deal," Trump wrote on Truth Social, offering no further details about the apparent agreement. Compared to Japan, the Philippines is a relatively small trade partner with the US. Last year it sent around $14.2bn worth of goods to America, including car parts, electric machinery, textiles and coconut oil. Japan welcomes US trade deal Japanese prime minister Shigeru Ishiba welcomed the US-Japan trade deal on Wednesday. He said: It comes as Japan was the fourth largest single-country export market for US agriculture and related products in 2022, valued at nearly $17bn (£12.5bn). This is according to a report from the International Trade Administration. The US was the country's largest supplier of food and agricultural products, followed by the EU, China, Australia, and Thailand. Japan was also the biggest export market for US beef and pork, valued at roughly $5bn combined, and the second largest market for US corn, valued at $3.3bn. Japanese prime minister Shigeru Ishiba welcomed the US-Japan trade deal on Wednesday. He said: It comes as Japan was the fourth largest single-country export market for US agriculture and related products in 2022, valued at nearly $17bn (£12.5bn). This is according to a report from the International Trade Administration. The US was the country's largest supplier of food and agricultural products, followed by the EU, China, Australia, and Thailand. Japan was also the biggest export market for US beef and pork, valued at roughly $5bn combined, and the second largest market for US corn, valued at $3.3bn. Asia and US overnight Stocks in Asia were higher overnight, with the Nikkei (^N225) surging 3.7% to a one-year high in Japan as the country struck a trade deal with the United States that lowers tariffs on its cars. US president Donald Trump said on Tuesday that a trade deal with Tokyo will include Japan paying a lower-than-threatened 15% tariff on shipments to the US. It also comes after an agreement with the Philippines that will see the US collect a 19% tariff rate on imports from there. Trump added that said representatives from the European Union were coming for trade negotiations on Wednesday, even as the EU was reportedly refining countermeasures in case of a deadlock before the 1 August deadline. Shares of carmakers surged on the back of the news with Mazda Motor (7261.T) rallying 17% and Toyota (7203.T) jumping more than 14%. Meanwhile the Hang Seng (^HSI) rose 1.3% in Hong Kong and the Shanghai Composite ( was 0.3% up by the end of the session. In South Korea, the Kospi (^KS11) added 0.4% on the day, with carmakers in the country also rising as the Japan deal fuelled optimism over potential progress in tariff negotiations between South Korea and the US. Across the pond on Wall Street, stocks inched to another record following some mixed profit reports. The S&P 500 (^GSPC) rose 0.1% to the all-time high it had set the day before, closing at 6,309.62, and the tech-heavy Nasdaq (^IXIC) slipped 0.4% from its own record, to 20,892.68. The Dow Jones (^DJI) gained 0.4% to end at 44,502.44. Stocks in Asia were higher overnight, with the Nikkei (^N225) surging 3.7% to a one-year high in Japan as the country struck a trade deal with the United States that lowers tariffs on its cars. US president Donald Trump said on Tuesday that a trade deal with Tokyo will include Japan paying a lower-than-threatened 15% tariff on shipments to the US. It also comes after an agreement with the Philippines that will see the US collect a 19% tariff rate on imports from there. Trump added that said representatives from the European Union were coming for trade negotiations on Wednesday, even as the EU was reportedly refining countermeasures in case of a deadlock before the 1 August deadline. Shares of carmakers surged on the back of the news with Mazda Motor (7261.T) rallying 17% and Toyota (7203.T) jumping more than 14%. Meanwhile the Hang Seng (^HSI) rose 1.3% in Hong Kong and the Shanghai Composite ( was 0.3% up by the end of the session. In South Korea, the Kospi (^KS11) added 0.4% on the day, with carmakers in the country also rising as the Japan deal fuelled optimism over potential progress in tariff negotiations between South Korea and the US. Across the pond on Wall Street, stocks inched to another record following some mixed profit reports. The S&P 500 (^GSPC) rose 0.1% to the all-time high it had set the day before, closing at 6,309.62, and the tech-heavy Nasdaq (^IXIC) slipped 0.4% from its own record, to 20,892.68. The Dow Jones (^DJI) gained 0.4% to end at 44,502.44. Coming up Good morning, and welcome back to our markets live blog. As usual we will be taking a deep dive into what's moving markets and happening across the global economy. To the day ahead we have data releases including US existing home sales for June, and the Euro Area's preliminary consumer confidence reading for July. Otherwise, earnings releases include Alphabet (GOOG) and Tesla (TSLA). Here's a snapshot of what's on the agenda: 7am: Trading updates: Kier, Compass Group, Mitie, Greencore, Marstons, ME Group 7am: UK Public Sector Net Borrowing 9.30am: Supreme Court to rule on appeal against LIBOR and EURIBOR convictions of Tom Hayes and Carlo Palombo 12pm: US weekly mortgage approvals data 3pm: US new home sales Good morning, and welcome back to our markets live blog. As usual we will be taking a deep dive into what's moving markets and happening across the global economy. To the day ahead we have data releases including US existing home sales for June, and the Euro Area's preliminary consumer confidence reading for July. Otherwise, earnings releases include Alphabet (GOOG) and Tesla (TSLA). Here's a snapshot of what's on the agenda: 7am: Trading updates: Kier, Compass Group, Mitie, Greencore, Marstons, ME Group 7am: UK Public Sector Net Borrowing 9.30am: Supreme Court to rule on appeal against LIBOR and EURIBOR convictions of Tom Hayes and Carlo Palombo 12pm: US weekly mortgage approvals data 3pm: US new home sales Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
